Key result
Continuing dual antiplatelet therapy beyond 12 months after PCI was associated with an increased rate of death from any cause compared to placebo (2% vs 1.5%; HR 1.36; 95% CI 1.00-1.85; P=0.05).
Why the study?
Does dual antiplatelet therapy beyond 12 months reduce ischemic events at the cost of increased bleeding in patients undergoing PCI for stable ischemic heart disease?
Does dual antiplatelet therapy beyond 12 months reduce ischemic events at the cost of increased bleeding in patients undergoing PCI for stable ischemic heart disease?
The decision to continue DAPT beyond 12 months after PCI should be individualized based on ischemic and bleeding risks, potentially utilizing risk stratification tools like the DAPT score.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bagur et al. (2018) conducted a review in Stable ischemic heart disease undergoing percutaneous coronary intervention (PCI). Dual antiplatelet therapy (DAPT) vs. Placebo / aspirin alone was evaluated on Death from any cause (HR 1.36, 95% CI 1.00-1.85, p=0.05). Continuing dual antiplatelet therapy beyond 12 months after PCI was associated with an increased rate of death from any cause compared to placebo (2% vs 1.5%; HR 1.36; 95% CI 1.00-1.85; P=0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: